genocea biosciences

Genocea Biosciences Receives Average Rating of "Buy" from Brokerages (NASDAQ:GNCA)
www.dakotafinancialnews.com

It's two product candidates in Phase II clinical development: GEN-003 and GEN-004. In addition, it has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including chlamydia genital herpes and malaria.

6
Like
Save
Genocea Biosciences Receives $24.00 Consensus Target Price from Analysts …
www.dakotafinancialnews.com

Additionally, it has product candidates, which are GEN 001, GEN-002 and GEN-005 in pre-clinical development for diseases, including chlamydia, genital herpes and malaria. It also creates a library of every protein in the proteome of the pathogen. It …

5
Like
Save
Zacks: Analysts Expect Genocea Biosciences to Post -$0.43 Earnings Per Share …
www.themarketbusiness.com

Additionally, it has product candidates, which are GEN001, GEN-002 and GEN-005 in pre-clinical development for diseases, including chlamydia, genital herpes and malaria. In addition, it creates a library of each protein in the proteome of the pathogen.

3
Like
Save
Stocks to Watch : SanDisk Corp. (NASDAQ:SNDK), Genocea Biosciences, Inc …
www.stocktranscript.com

Genocea said that pending further review of the data and potential paths forward, it plans to turn its focus to its immunotherapy treatment for genital herpes—known as GEN-003—which also is in phase 2 development. Genocea Biosciences, Inc.

2
Like
Save
Today's Watch List: General Motors Company (NYSE:GM), Genocea Biosciences, Inc …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
3 Biotech Stocks Are Getting Crushed: Genocea Biosciences Inc(NASDAQ:GNCA …
www.wallstreetpoint.com

“For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase 2 program for GEN-003, our immunotherapy for genital herpes, for which we recently announced positive six-month …

7
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save